An analysis of the attrition of drug candidates from four major pharmaceutical companies
Michael J. Waring(Newcastle University), Alex. M. Weir(Thomson Reuters (United Kingdom)), Paul D. Leeson(RED Consulting (Norway)), Ji‐Bo Wang(Kunming University of Science and Technology), Owen B. Wallace(Eli Lilly (United States)), Robert M. Owen(Pfizer (United States)), Stephen D. Pickett(Ligand Pharmaceuticals (United Kingdom)), Garry Pairaudeau(AstraZeneca (United Kingdom)), John Arrowsmith(Thomson Reuters (United Kingdom)), Sam Mandrell(Thomson Reuters (United Kingdom)), William D. Pennie(Pfizer (United States)), Andrew R. Leach(LifeArc)
Cited by 1,434
Related Papers
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
|Journal of Molecular Biology|1997|6.7k
ChEMBL: towards direct deposition of bioassay data
|Nucleic Acids Research|2018|2.5k
The ChEMBL database in 2017
|Nucleic Acids Research|2016|2.4k
Molecular Modelling: Principles and Applications
|Unknown|1996|1.9k
The ChEMBL Database in 2023: a drug discovery platform spanning multiple bioactivity data types and time periods
|Nucleic Acids Research|2023|1.3k